Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Shire
 More »

  • Shire Renews Rare Genetic Disease Collab with Santaris
    In what was surely music to Santaris' ear, Shire extended an existing agreement, saying, ... the terms of the extended agreement, Shire will have the right to nominate additional ...
    8-23-2013
  • Big Need in IBD: Drugs to Slow Progression
    ... Lialda®, by Shire, is another gut-selective reformulation. The drug was reintroduced two ... In May 2013, Shire gained an injunction against Watson Pharmaceuticals Group and its ...
    8-1-2013
  • Top 25 Biotech Companies of 2013
    ... 211,061,148 shares * price $38.62) % Change: 114.6% Position on 2012 List: #11 #11. Shire 2013 Market Cap: $17.252 billion (4/29: 562,826,237 shares * price £20.17) 2012 Market ...
    7-15-2013
  • Top 20 Corporate Venture Funds
    ... creation of spinoff companies Year established: 2012 #15. Strategic Investment Group (Shire) Resources: $50 million in initial capital funding Current portfolio: Number of ...
    6-14-2013
  • Flexibility in Biopharmaceutical Manufacturing Capacity
    Single-use bioreactors are changing the biomolecular production landscape. Biologic drugs including monoclonal antibodies, therapeutic proteins, immunotherapies, and vaccines have ...
    5-28-2013
  • Nimbus, Shire Collaborate to Co-Develop Small Molecule Treatments
    Nimbus Discovery has entered a co-development agreement with Shire focused on small molecule treatments for lysosomal storage disorders (LSDs), the firm said. Nimbus and Shire hope ...
    5-8-2013
  • Single-Use Bioreactor Roundup
    ... Also, companies are now bringing on line single-use plants, as recently announced by Shire, and are beginning to utilize bioreactors. Geographically, we are seeing growth in all ...
    4-15-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    ... 1, 2012, citing the EU market exclusivity until 2020 of a competing agent from Shire #10. Linzess(tm) (linaclotide) 2012 sales: $19.2 million 9 Marketer(s): Ironwood ...
    4-4-2013
  • Shire Buys SARcode Bioscience for $160M+
    Shire said today it will acquire drug developer SARcode Bioscience, in a $160 million-plus ... Shire will pay SARcode Bioscience $160 million up-front, plus additional payments to be ...
    3-25-2013
  • Shire Expands Into Neonatology with Premacure Acquisition
    therapeutic offerings into neonatology, Shire said today it is buying Swedish-owned ... The price was not disclosed, although Shire said it will acquire Premacure for an up-front ...
    3-12-2013
  • Adderall Generics and Legal Woes Hurt Shire
    Shire profits during the fourth quarter of 2012-though the company says it is in strong shape this year following investments in late-stage pipeline drug candidates. Shire saw ...
    2-14-2013
  • Shire Acquires Lotus Tissue Repair
    Shire said today it will acquire Lotus Tissue Repair, the privately-held developer of the ... The price was not disclosed, though Shire said it would make an up-front payment as well ...
    1-8-2013
  • GPCRs Targeted in Heptares/Cubist Collab
    Also, in March of last year, Shire made a potentially $190 million deal with Heptares for an exclusive worldwide license to Heptares' adenosine A 2A receptor antagonist candidate ...
    1-7-2013
  • Shire Rare-Disease Partnerships Expand
    Shire today broadened its research partnership efforts aimed at rare disease, launching a ... Under the alliance with German-owned ethris, Shire will develop mABs using its partner's ...
    1-7-2013
  • The New Economics of Orphan Diseases
    ... Shire is among them. It formed a strategic collaboration with Sangamo BioSciences in ... Shire also is developing therapeutics for mucopolysaccharidosis type II (Hunter syndrome), ...
    1-1-2013

  • Journal Articles

  • Measurement of Skin Desmosine as an Indicator of Altered Cutaneous...
    Hilde E.V. De Cock, Verena K. Affolter, Thomas B. Farver, Leen Van Brantegem, Brad Scheuch, Gregory L. Ferraro
    Lymphatic Research and Biology
    Lymphatic Research and Biology Background: Chronic progressive lymphedema in Clydesdale and Shire draft horses causes severe disability of the limbs which leads to premature death ...
  • A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetam...
    Robert Findling, Andrew J Cutler, Keith Saylor, Maria Gasior, Mohamed Hamdani, M. Celeste Ferreira-Cornwell, Ann Catherine Childress
    Journal of Child and Adolescent Psychopharmacology
    This study aimed to assess safety and effectiveness of lisdexamfetamine dimesylate (LDX; Vyvanse®, Shire US Inc., Wayne, PA, USA) over 52 weeks in adolescents with ADHD. Methods: ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll